Natural Product (NP) Details
| General Information of the NP (ID: NP7687) | |||||
|---|---|---|---|---|---|
| Name |
Pterostilbene
|
||||
| Synonyms |
4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus; pterostilbene; 537-42-8
Click to Show/Hide
|
||||
| Species Origin | Vitis vinifera ... | Click to Show/Hide | |||
| Vitis vinifera | |||||
| Pterocarpus indicus | |||||
| Disease | Cardiomyopathy [ICD-11: BC43] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.877
MDCK Permeability
-4.733
PAMPA
- - -
HIA
- - -
Distribution
VDss
0.012
PPB
90.5%
BBB
- - -
Metabolism
CYP1A2 inhibitor
+++
CYP1A2 substrate
- - -
CYP2C19 inhibitor
+
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
++
CYP2D6 inhibitor
+
CYP2D6 substrate
+++
CYP3A4 inhibitor
+++
CYP3A4 substrate
- - -
CYP2B6 inhibitor
+++
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
-
Excretion
CLplasma
11.638
T1/2
0.868
Toxicity
DILI
-
Rat Oral Acute Toxicity
- -
FDAMDD
++
Respiratory
+
Human Hepatotoxicity
++
Ototoxicity
- -
Drug-induced Nephrotoxicity
-
Drug-induced Neurotoxicity
++
Hematotoxicity
- -
Genotoxicity
-
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C16H16O3
|
||||
| PubChem CID | |||||
| Canonical SMILES |
COC1=CC(=CC(=C1)C=CC2=CC=C(C=C2)O)OC
|
||||
| InChI |
1S/C16H16O3/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11,17H,1-2H3/b4-3+
|
||||
| InChIKey |
VLEUZFDZJKSGMX-ONEGZZNKSA-N
|
||||
| CAS Number |
CAS 537-42-8
|
||||
| Herb ID | |||||
| SymMap ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| 3-methyladenine | Cardiac injury | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| BT-549 | CVCL_1092 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The anti-tumor efficiency of pterostilbene is promoted with a combined treatment of Fas signaling or autophagy inhibitors in triple negative breast cancer cells. | |||||
| Osimertinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | CDCP1 | Molecule Info | ||
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | YAP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | |||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The combination of osimertinib and pterostilbene reversed the osimertinib-induced STAT3, YAP1, and CUB domain-containing protein-1 (CDCP1) phosphorylation and slightly suppressed Src phosphorylation in PC9 and H1975 cells. | |||||
| TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | DDIT3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | BT-20 | CVCL_0178 | Invasive breast carcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| MDA-MB-468 | CVCL_0419 | Breast adenocarcinoma | Homo sapiens | |||
| HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | |||
| SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | |||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
| A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
| NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Pterostilbene enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistance triple negative breast cancer cells. | |||||
| Vorinostat | Mycosis fungoides | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | HIF-1A | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MTA1 | Molecule Info | |||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
| In-vivo Model | Female C57BL/6J mouse homozygous with "floxed" allele of Pten gene were used in this study. | |||||
| Experimental
Result(s) |
Pterostilbene sensitized tumor cells to SAHA treatment resulting in inhibiting tumor growth and additional decline of tumor progression. These effects were dependent on the reduction of MTA1-associated proangiogenic factors HIF-1Alpha, VEGF, and IL-1Beta leading to decreased angiogenesis. | |||||
| Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-N87 | CVCL_1603 | Gastric tubular adenocarcinoma | Homo sapiens | ||
| MKN45 | CVCL_0434 | Gastric adenocarcinoma | Homo sapiens | |||
| In-vivo Model | N87 cells (3*105 cells) were suspended in 0.1 mL of PBS and inoculated subcutaneously into the right flank of five-week-old male BALB/c nude mice. | |||||
| Experimental
Result(s) |
PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis. | |||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | FOXO1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | IFI27 | Molecule Info | |||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Caco-2 | CVCL_0025 | Colon adenocarcinoma | Homo sapiens | ||
| HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Pterostilbine sensitizes colon cancer cells to 5-fluorouracil cytotoxicity. | |||||
| Tamoxifen | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [8] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| ZR-75-1 | CVCL_0588 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Pterostilbene shows an additive inhibitory effect on breast cancer cells when combined with tamoxifen, most likely from augmented cancer cell apoptosis. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Molecule Info | [9] | |
| PPAR-alpha (PPARA) | Molecule Info | [10] | ||
| KEGG Pathway | PPAR signaling pathway | Click to Show/Hide | ||
| 2 | cAMP signaling pathway | |||
| 3 | Adipocytokine signaling pathway | |||
| 4 | Glucagon signaling pathway | |||
| 5 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 6 | Hepatitis C | |||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | Click to Show/Hide | ||
| Reactome | RORA activates gene expression | Click to Show/Hide | ||
| 2 | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
| 3 | PPARA activates gene expression | |||
| 4 | YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||
| 5 | Transcriptional activation of mitochondrial biogenesis | |||
| 6 | Activation of gene expression by SREBF (SREBP) | |||
| 7 | Transcriptional regulation of white adipocyte differentiation | |||
| 8 | Nuclear Receptor transcription pathway | |||
| 9 | Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| 10 | Circadian Clock | |||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | Click to Show/Hide | ||
| 2 | Nuclear Receptors Meta-Pathway | |||
| 3 | Estrogen Receptor Pathway | |||
| 4 | PPAR Alpha Pathway | |||
| 5 | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| 6 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 7 | YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||
| 8 | Activation of Gene Expression by SREBP (SREBF) | |||
| 9 | Adipogenesis | |||
| 10 | SREBF and miR33 in cholesterol and lipid homeostasis | |||
| 11 | Circadian Clock | |||
| 12 | Nuclear Receptors | |||